ASCO 2024: Updates in the Treatment of Advanced Renal Cell Carcinoma - Episode 13

Select Ongoing Trials for nccRCC and Impact on the Treatment Landscape

, , ,

  1. Please review ongoing trials for patients with nccRCC and discuss the potential impact of these studies on the treatment landscape.
  2. Phase 2 KEYNOTE-B61 trial, comparing len + pembro in 1L nccRCC 
  3. Please provide a brief background surrounding KEYNOTE-B61
  4. Please discuss extended follow-up presented at ASCO GU 2024
  5. Phase 2 trial assessing nivo + cabo (